Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study

Background Metformin, in the absence of contraindications or intolerance, is recommended as first-line treatment for patients with type 2 diabetes mellitus (T2DM). This observational, retrospective study assessed the real-world adequacy of glycaemic control in Greek patients with T2DM initiating metformin monotherapy at maximum tolerated dose. Methods Included patients received metformin monotherapy for ≥24 months; relevant patient data were collected immediately prior to metformin initiation (baseline) and at other prespecified time points. The primary objective was to report, after 9 months of metformin treatment, the percentage of patients with baseline glycated haemoglobin (HbA 1c ) levels ≥6.5% (≥48 mmol/mol) achieving HbA 1c 1c ≥7% (≥53 mmol/mol) achieving HbA 1c Results Of the enrolled patients (N=316), 247 had baseline HbA 1c ≥6.5%; following 9 months on metformin, 90 (36.4%) patients achieved HbA 1c 1c change−1.3% [−14 mmol/mol]). Median time of exposure to HbA 1c ≥6.5% was 23.4 months and time to treatment intensification was 28.0 months. The sensitivity analysis revealed that the proportion of patients achieving HbA 1c 1c change −1.6% [−17 mmol/mol]). Conclusion Irrespective of HbA 1c target assessed, most patients with T2DM do not achieve the recommended HbA 1c goals after 9 months on metformin while remained on monotherapy for up to 24 months. Addressing clinical inertia could improve disease outcomes and, possibly, economic burden.